PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
=== Effects on identity === Human enhancement technologies can impact human identity by affecting one's self-conception. The argument does not necessarily come from the idea of improving the individual but rather changing who they are and becoming someone new. Altering an individual identity affects their personal story, development and mental capabilities. The basis of this argument comes from two main points: the charge of inauthenticity and the charge of violating an individual's core characteristics. Gene therapy has the ability to alter one's mental capacity, and through this argument, has the ability to affect their narrative identity. An individual's core characteristics may include internal psychological style, personality, general intelligence, necessity to sleep, normal aging, gender and being Homo sapiens. Technologies threaten to alter the self fundamentally to the point where the result is, essentially, a different person entirely. For example, extreme changes in personality may affect the individual's relationships because others can no longer relate to the new person. The capability approach focuses on a normative framework that can be applied to how human enhancement technologies affects human capabilities. The ethics of this does not necessarily focus on the make up of the individual but rather what it allows individuals to do in today's society.
Repeated drug exposure changes how genes are switched on and off in the brain's reward circuits without altering the underlying DNA sequence, a set of processes known as epigenetic regulation. Three kinds of change have been implicated: chemical modification of the histone proteins around which DNA is wound, methylation of the DNA itself, and altered levels of small regulatory molecules called microRNAs. In rodents, some drug-induced epigenetic marks can be passed from parent to offspring and alter the offspring's response to the same drug, in some experiments reducing rather than increasing their drug taking. Neither the inheritance of these marks in humans nor their behavioral effects has been established.
== History == Thiotepa and its synthesis were patented in 1952 by the American Cyanamid company. It was made for use in the textile industry and in the production process of plastics. However, thiotepa entered human trials in 1953 and was found to be effective against acute myeloid leukemia, chronic myelogenous leukemia, and Hodgkin's lymphoma. The first clinical trial noted a "reasonable margin for safety" between the apparent dose and undesired bone marrow suppression In January 2007, the European Medicines Agency (EMA) designated thiotepa as an orphan drug. In April 2007, the United States FDA designated thiotepa as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In June 2024, the FDA approved a ready-to-dilute liquid formulation of thiotepa to treat breast and ovarian cancer.
Sources: en.wikipedia.org
On August 22, 2018, Alice in Chains sent fans on a scavenger hunt to access a secret gig that the band would be performing in Seattle on August 24. Ten signed CD copies of Rainier Fog were hidden around the city as a ticket into the show, and the band asked the fans to keep an eye on their Instagram story for details on the 10 hidden locations. Once all 10 albums were found, the band revealed that the secret gig would be at the rock club The Crocodile, with limited tickets available with the purchase of their album at a pop-up event at the same venue the next day. Preview clips of each of the album tracks were posted on the band's Instagram. The band also commemorated the release of the album with a pop-up museum installation at The Crocodile in Seattle on August 23 and 24. The museum featured rare Alice in Chains photos, limited-edition merchandise and memorabilia that showcased the band's 30+ year career. Rainier Fog debuted at No. 12 on the Billboard 200 chart, selling 31,000 copies (29,000 in traditional album sales), in its first week of release. The album also debuted at No. 1 on Billboard's Top Rock Albums, Alternative Albums and Hard Rock Albums charts, and at No. 3 on the Vinyl Albums chart. Rainier Fog became Alice in Chains' first top 10 in the UK, peaking at No. 9, and topping UK's Rock & Metal Albums chart. The album has been nominated for a Grammy Award for Best Rock Album.
In the beginning of the 19th century the process of canning foods was mainly done by small canneries. These canneries were full of overlooked sanitation problems, such as poor hygiene and unsanitary work environments. Since the refrigerator did not exist and industrial canning standards were not set in place it was very common for contaminated cans to slip onto the grocery store shelves. According to The Fruits of Empire: Art, Food and the Politics of Race in the Age of American Expansion by Shana Klein, "Workers also suffered injuries, specifically bruised knuckles and open sores, from trimming and packaging pineapples. Gloves were one preventative measure to protect a canner's hands from the acidity of the pineapple, but gloves did not always help."
Beaumont said that with the exception of the Kreis Stuhm, where Poles admittedly numbered 15,500 out of a population of 36,500 (42%), they had Polish sympathies since they were Catholics. In the other districts, with the exception of Allenstein, Poles depicting themselves as Mazurians were Lutherans and German in a national conviction. On the eve of the plebiscite, Beaumont reported that Poles strictly guarded the new frontier between East Prussia and Poland to prevent people from passing to East Prussia without vexatious formalities. They held up trains for hours and constantly interrupted or even completely suppressed postal, telegraphic and telephonic communication service. The great bridge over the Vistula at Dirschau was barred by sentries in French uniforms, "who refuse to understand any language but Polish". As a result, Beaumont wrote that area to have been "cut off from its shopping centre and chief port almost completely". After the plebiscite, the bridge was removed. To Beaumont, it would be "desirable to convey a hint to the Warsaw Government that their present policy is scarcely calculated to gain them votes". Sir Horace Rumbold, the British minister in Warsaw, also wrote to George Curzon on 5 March 1920 that the Plebiscite Commissions at Allenstein and Marienwerder "felt that they were isolated both from Poland and from Germany" and that the Polish authorities were holding up supplies of coal and petrol to those districts.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.